2-(3-溴苯基)乙酰氯 | 98288-51-8

• 物质功能分类: 化学试剂 - 有机试剂 - 酰卤
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(3-溴苯基)乙酰氯
• 中文别名: 3-溴苯乙酰氯
• 英文名称: 2-(3-bromophenyl)acetyl chloride
• 英文别名: 3-bromophenylacetyl chloride；meta-bromophenylacetyl chloride；2-(m-bromophenyl)acetyl chloride
• CAS: 98288-51-8
• 化学式: C₈H₆BrClO
• 分子量: 233.492
• InChiKey: DFKQZCVLSJIRES-UHFFFAOYSA-N

物化性质

• 沸点：
  284.6±23.0 °C(Predicted)
• 密度：
  1.547 g/mL at 25 °C
• 闪点：
  >110℃

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S36,S39
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2916399090

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : 3-BROMOPHENYLACETYL CHLORIDE
CAS-No. : 98288-51-8
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Skin irritation (Category 2)
Eye irritation (Category 2)
Specific target organ toxicity - single exposure (Category 3)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Irritating to eyes, respiratory system and skin.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R36/37/38 Irritating to eyes, respiratory system and skin.
S-phrase(s)
S36 Wear suitable protective clothing.
S39 Wear eye/face protection.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C8H6BrClO
Molecular Weight : 233,49 g/mol
Component Concentration
3-BROMOPHENYLACETYL CHLORIDE
CAS-No. 98288-51-8 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly
investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIRE-FIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, Hydrogen chloride gas, Hydrogen bromide gas
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid breathing vapors, mist or gas. Ensure adequate ventilation.
Evacuate personnel to safe areas.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the
environment must be avoided.
Methods and materials for containment and cleaning up
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Containers which are
opened must be carefully resealed and kept upright to prevent leakage.
Handle and store under inert gas.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at
the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and
approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the
standard EN 374 derived from it.
Body Protection
impervious clothing, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator with
multi-purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup to
engineering controls. If the respirator is the sole means of protection, use a full-face supplied air
respirator. Use respirators and components tested and approved under appropriate government
standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: liquid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point > 110 °C
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density 1,547 g/cm3
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 2,843
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. Causes skin irritation.
Eyes Causes serious eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly
investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
Harmful to aquatic life.
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(3-溴苯基)乙酰氯 在 氢氧化钾 、 四(三苯基膦)钯 、 三氯化铝 、 硫酸 、 potassium tert-butylate 、 三溴化硼 、 sodium carbonate 、 一水合肼 作用下， 以 二氯甲烷 、 二甲基亚砜 、 1,2-二氯乙烷 、 甲苯 为溶剂， 反应 53.0h， 生成 methyl 3-(2-hydroxy-5-{2-[3-(2-hydroxyphenyl)phenyl]ethyl}phenyl)phenylacetate
  参考文献：
  名称：

  选择素介导的细胞粘附的新型合成抑制剂：1，6-双[3-（3-羧甲基苯基）-4-（2-α-D-甘露吡喃糖基氧基）苯基]己烷（TBC1269）的合成。

  摘要：

  E-选择素的高亲和力配体，唾液酸二-Lewis（x）（sLe（x）Le（x），1）的报道促使我们将对先前报道的基于联苯的抑制剂进行修饰，从而提供与蛋白质。分析了这些化合物抑制带有唾液酸的Lewis（x）（sLe（x），2）HL-60细胞与E-，P-和L-选择蛋白融合蛋白结合的能力。我们报告说，包含简单的非寡糖选择素拮抗剂的多个组成部分的二聚体或三聚体化合物抑制sLe（x）依赖性结合，并具有比单体化合物显着增强的效力。增强的效力与单个选择素凝集素结构域内的其他结合相互作用一致。然而，不能排除与多个凝集素结构域的多价相互作用。

  DOI：

  10.1021/jm9704917
• 作为产物：
  描述：

  间溴苯甲酸 在 草酰氯 、 N,N-二甲基甲酰胺 、 silver(l) oxide 作用下， 以 1,4-二氧六环 、 乙醚 、 二氯甲烷 为溶剂， 生成 2-(3-溴苯基)乙酰氯
  参考文献：
  名称：

  Quinolones as gonadotropin releasing hormone (GnRH) antagonists: simultaneous optimization of the C(3)-aryl and C(6)-substituents

  摘要：

  A series of 3-arylquinolones was prepared and evaluated for their ability to act as gonadotropin releasing hormone (GnRH) antagonists. A variety of substitution patterns of the 3-aryl substituent are described. The 3,4,5-trimethylphenyl substituent (23h) was found to he optimal. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00318-8

文献信息

• 吡唑并[3,4-c]吡啶类衍生物
  申请人：石药集团中奇制药技术(石家庄)有限公司

  公开号：CN105384739B

  公开（公告）日：2020-03-20

  吡唑并[3,4‑c]吡啶类衍生物。本发明涉及下式（I）的化合物，其互变异构体、其光学异构体、或其药学上可接受的盐：Z，X，RNc，RNd，RNe和RNf如权利要求1所定义。本发明还涉及包含上述化合物的药物组合物。本发明还涉及上述化合物或药用组合物在制备用于预防和/或治疗抑制Xa因子正性影响疾病的药物中的用途，特别是在制备用于在低出血风险的情况下预防和/或治疗抑制Xa因子正性影响疾病的药物中的用途。
• Practical and Chemoselective Reduction of Acyl Chloride to Alcohol by Borohydride in Aqueous Dichloromethane
  作者：Ramya Rajan、Sachin Badgujar、Kamaljit Kaur、Yashwardhan Malpani、Pranab R. Kanjilal

  DOI：10.1080/00397910903340645

  日期：2010.8.31

  simple methodology for the reduction of acid chlorides to their corresponding alcohols has been developed. Various carboxylic acids were converted to alcohols in excellent yields using NaBH4-K2CO3 in a mixed solvent system of dichloromethane and water (1:1) in the presence of a phase-transfer catalyst at low temperature. The importance of the work is its simplicity, selectivity, excellent yield, and very

  已开发出一种将酰氯还原为其相应醇的简单方法。在低温相转移催化剂的存在下，在二氯甲烷和水 (1:1) 的混合溶剂体系中，使用 NaBH4-K2CO3 将各种羧酸转化为醇，收率极好。这项工作的重要性在于它的简单性、选择性、出色的收率和非常短的反应时间。这种新的还原条件已被证明是在各种官能团存在下对一系列酰氯的出色化学选择性方法。
• Cycloalkyl amino-hydantoin compounds and use thereof for beta-secretase modulation
  申请人：Malamas Sotirios Michael

  公开号：US20070027199A1

  公开（公告）日：2007-02-01

  The present invention provides a 2-amino-5-cycloalkyl-hydantoin compound of formula I The present invention also provides methods and compositions for the inhibition of β-secretase (BACE) and the treatment of β-amyloid deposits and neurofibrillary tangles.

  本发明提供了一种公式I的2-氨基-5-环烷基乙内酰脲化合物。 本发明还提供了一种用于抑制β-分泌酶（BACE）以及治疗β-淀粉样蛋白沉积和神经纤维缠结的方法和组合物。
• Design and synthesis of thiazole derivatives as potent FabH inhibitors with antibacterial activity
  作者：Jing-Ran Li、Dong-Dong Li、Rong-Rong Wang、Jian Sun、Jing-Jun Dong、Qian-Ru Du、Fei Fang、Wei-Ming Zhang、Hai-Liang Zhu

  DOI：10.1016/j.ejmech.2013.11.020

  日期：2014.3

  bond between aromatic acid and 4-phenylthiazol-2-amine or 4-(4-bromophenyl)thiazol-2-amine. These thiazole derivatives have evaluated as potent FabH inhibitors. Nineteen compounds (4b–4h, 4k, 4l, 5a–5h, 5k, 5l) are reported for the first time. Most of the synthesized compounds exhibited antibacterial activity in the MTT assay. The MIC value of these compounds ranged from 1.56 μg/mL to 100 μg/mL. Moreover

  脂肪酸生物合成途径的组成已被确定为开发新型抗菌剂的有吸引力的目标。A系列（4a - 4g）和B系列（5a - 5g）的化合物是通过在芳族酸和4-苯基噻唑-2-胺或4-（4-溴苯基）噻唑-2-胺之间形成胺键合成的。这些噻唑衍生物已被评估为有效的FabH抑制剂。19种化合物（4b – 4h，4k，4l，5a – 5h，5k，5l）是首次报告。大多数合成的化合物在MTT分析中显示出抗菌活性。这些化合物的MIC值在1.56μg/ mL至100μg/ mL的范围内。此外，测试化合物还显示出FabH抑制能力，IC 50值在5.8μM至48.1μM的范围内。IC 50值接近MIC值。化合物5f具有最佳的抗菌和大肠杆菌FabH抑制活性。进行了对接模拟和QSAR研究，以了解结合模式以及结构与活性之间的关系。
• Discovery of a potent protein kinase D inhibitor: insights in the binding mode of pyrazolo[3,4-d]pyrimidine analogues
  作者：Klaas Verschueren、Mathias Cobbaut、Joachim Demaerel、Lina Saadah、Arnout R. D. Voet、Johan Van Lint、Wim M. De Borggraeve

  DOI：10.1039/c6md00675b

  日期：——

  PKD inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold. The lead compound for this study was 1-NM-PP1, which was previously found by us and others to inhibit PKD. In our screening we identified one compound (3-IN-PP1) displaying a 10-fold increase in potency over 1-NM-PP1, opening new possibilities for specific protein kinase inhibitors for kinases that show sensitivity towards pyrazolo[3,4-d]pyrimidine

  在本研究中，我们着手基于吡唑并[3,4- d ]嘧啶支架合理优化PKD抑制剂。本研究的先导化合物是 1-NM-PP1，我们和其他人之前发现它可以抑制 PKD。在我们的筛选中，我们鉴定出一种化合物 (3-IN-PP1)，其效力比 1-NM-PP1 提高 10 倍，为对吡唑并显示敏感性的激酶的特定蛋白激酶抑制剂开辟了新的可能性[3,4- d ]嘧啶衍生的化合物。有趣的是，观察到的 SAR 与通常观察到的结合模式并不完全一致，其中吡唑并[3,4- d ]嘧啶化合物以与 PKD 天然配体 ATP 类似的方式结合。因此，我们建议采用另一种结合模式，其中化合物翻转 180 度。这种基于吡唑并[3,4- d ]嘧啶的化合物的可能的替代结合模式可以为用于对吡唑并[3,4- d ]嘧啶敏感的激酶的新型特异性蛋白激酶抑制剂铺平道路。